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Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney
tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ
transplantation. Based on an observation that PPARγ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a
Cl− transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl− secretory response to vasopressin
in cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth. The current studies show that a 7- or 14-
week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to
human PKD. These studies provide proof of concept for the mechanism of action of the PPARγ agonists and suggest that this class
of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.
1. Introduction
Agonists of the peroxisome proliferator activator receptor
gamma (PPARγ) have pleiotropic effects on intermediary
metabolism. Two of these agents, rosiglitazone and piogli-
tazone, are approved for clinical use as insulin-sensitizing
agents in the treatment of type II diabetes. One of the major
side effects of PPARγ treatment is fluid retention that can,
in some instances, result in overt edema [1–3]. A renal
collecting duct-specific knockout of PPARγ in rodent models
abrogates the drug-induced fluid retention, suggesting that
the effect arises from alterations in electrolyte and/or fluid
transport in the distal nephron [4, 5]. Studies in a cell culture
model of the principal cell type of the distal nephron have
demonstrated that PPARγ agonists inhibit cAMP-stimulated
anion transport and themRNA expression of the cystic fibro-
sis transmembrane conductance regulator (CFTR), a Cl−
channel found in the apical membrane of this cell type [6].
Polycystic kidney disease (PKD) is a genetic disease
with both autosomal dominant (ADPKD) and autosomal
recessive (ARPKD) forms [7, 8]. ADPKD is the more
prevalent form, striking approximately 1 in 1000 in the
adult population and presenting as slow growing, fluid-filled
cysts which form predominately in the kidney. Progressive
cyst growth and fibrosis in the surrounding tissue generally
compromise organ function after middle age and lead to
end-stage renal disease after the fifth decade. ARPKD affects
children in the neonatal period and is characterized by
tubular dilation. Both forms of PKD have liver involvement
with cysts that arise from cholangiocytes, an epithelial cell
type lining the hepatic bile ducts.
The genes that are mutated in PKD encode proteins
found in the primary cilia, cytoplasmic vesicles, endoplasmic
reticulum, and cell-cell and cell-extracellular matrix con-
tacts. These proteins are either transient receptor potential
Ca2+ channels or proteins that regulate this class of Ca2+
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channels [7, 8]. Disease-associated decreases in intracellular
Ca2+ concentrations modulate intracellular signaling path-
ways including those regulating cAMP and Cl− channels.
It is widely accepted that secretion of ions and fluid by
the cyst-lining epithelial cells contribute to cyst expansion.
Studies performed over a decade ago indicate that renal
cyst formation in PKD is driven by anion (Cl− or HCO−3 )
secretion [9–11], and more recent studies have shown a
remarkably similar profile in freshly isolated bile duct epithe-
lia [12]. Inhibitor studies and electrophysiological analyses
have shown that CFTR is the Cl− channel responsible for
secretion in both kidney and biliary cysts [10, 12]. Based
on the previous finding that PPARγ agonists inhibit CFTR
expression [6], the current studies were designed to test the
efficacy of a PPARγ agonist, pioglitazone, in inhibiting cyst
growth.
Of the several rodent models for PKD, we chose to use
the PCK rat model because the genetic mutation in this
animal is orthologous to human ARPKD, while the animals
also express many of the phenotypic characteristics of human
ADPKD [13, 14]. The animals develop both kidney and liver
fibrocystic diseases and live long enough to facilitate long-
term treatment protocols. This model was used in preclinical
testing of both the renal V2 receptor antagonist and the
somatostatin agonist as treatment options for PKD [15–17].
2. Subjects and Methods
2.1. Animals. PCK rats were purchased from Charles River
Laboratories, Inc. (Wilmington, MA) or were bred in the
colonies at Indiana University School of Medicine (IUSM)
or the Mayo Clinic. Institutional Animal Care and Use Com-
mittees at each institution approved all protocol procedures.
The amount of pioglitazone added to the chow was based on
the estimated animal consumption of the base diets.
2.2. Study Design and Protocol
2.2.1. IUPUI. After weaning, at four weeks of age, rodents
were randomly separated into treatment and control groups.
The treatment groupwas fed Purina no. 5002 Labdiet supple-
mented with pioglitazone calculated to provide 20mg/kg BW
when provided ad libitum. Control rodents were fed unsup-
plemented Purina no. 5002 Labdiet. At week 18, rodents
were anesthetized with 100mg/kg intraperitoneally injected
sodium pentobarbital. Blood was collected via intracardiac
puncture and analyzed for plasma chemistries at the Clarion
Pathology Laboratories of the Indiana University School of
Medicine. After a laparotomy, the organs were flushed with
saline, and the left kidney and right liver lobe were collected
and frozen in liquid nitrogen. The remaining kidney and
liver were infused with 4% paraformaldehyde, removed, and
stored in 4% paraformaldehyde for histology. Kidney and
liver were embedded in paraffin and sectioned transversely
(4 μM sections).
2.2.2. Mayo. Treatment with pioglitazone was started at
the time of weaning or three weeks of age. Pioglitazone
(Takeda Chemical Industries) was added to the food at
concentrations estimated to provide 4 or 20mg/kg/day. The
control animals received unsupplemented diet. At the end of
each study, rats were anesthetized with ketamine 60mg/kg
and xylazine 10mg/kg, IP. Blood was obtained by cardiac
puncture for determination of plasma creatinine, BUN,
electrolytes, bilirubin, liver enzymes, and glucose. The right
kidney, part of the liver, the pancreas, and the spleen were
placed into preweighed vials containing 10% formaldehyde
in phosphate buffer (pH 7.4). These tissues were embedded
in paraffin for histological studies. The left kidney and part
of the liver were immediately frozen in liquid nitrogen.
2.3. Histological Analyses
2.3.1. IUPUI. Medial transverse kidney sections were stained
with hematoxylin, and eosin and cyst volumes were ana-
lyzed using point count stereology methods on deidentified
sections [18]. Kidney and liver fibrosis was assessed with
picrosirius red staining. Kidney fibrosis was graded on a
scale of 1–4 (1-normal, 2-slight, 3-moderate, and 4-severe)
in both the cortex and the juxtamedullary areas of the kidney.
Similarly, liver fibrosis was assessed on a scale of 1–4 (1-
less than 1% fibrosis, 2-less than 5% fibrosis, 3-less than
20% fibrosis, and 4-greater than 20% fibrosis). All scoring
was done by trained scientists blinded to the identity of the
sections.
2.3.2. Mayo. Four μm transverse tissue sections of the kid-
ney, including cortex, medulla, and papilla, and of the liver
were stained with hematoxylin-eosin and picrosirius red.
Whole transverse tissue sections stained with hematoxylin-
eosin were used to measure cyst volumes. Renal and hepatic
fibrosis was scored using the picrosirius red staining. Image
analysis procedures were performed without knowledge of
group assignments using Meta-Morph software (Universal
Imaging, West Chester, PA). Stained sections were visualized
and digital images were acquired using a high-resolution
Nikon Digital camera and displayed on the monitor. Def-
inition of interested structures and exclusion of fields too
damaged to be analyzed were achieved by interactively
applied techniques of enhancement. Colored thresholds were
applied at levels which separate cysts from noncystic tissue.
Kidney and liver fibrosis were graded as above.
2.4. Electron Microscopy Studies. Small pieces of the perfu-
sion fixed kidney were processed for electron microscopic
immunogold labeling in the IU School of Medicine Electron
Microscopy Center (http://www.anatomy.iupui.edu/corefac/
emcenter.php) using a standard postembedding labeling
technique. Kidney pieces which had visible cysts were
trimmed to 2 × 2mm segments which were dehydrated
and embedded in Unicryl (Electron Microscopy Sciences,
Hatfield, PA). Thin sections (70–90 nm) were mounted on
Formvar/carbon coated nickel grids, rinsed with PBS, and
grids placed in blocking buffer (2% BSA, 0.1% Cold Water
Fish Gelatin, and 0.1% Tween in PBS) for 30–45 minutes.
The grids were then placed in the primary antibody (mouse
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monoclonal anti-CFTR antibody, 596, 1 : 5, kindly provided
by John R. Riordan, University of North Carolina) overnight
at 4◦C in a humid chamber. The grids were then rinsed
with PBS and floated on drops of the appropriate secondary
antibody with attached 10 nm colloidal gold (AURION,
Hatfield, PA) for 2 hours at room temperature and rinsed
with PBS. To more firmly adfix the antibody bindings, grids
were placed in 2.5% Glutaraldehyde in 0.1M Phosphate
buffer for 15 minutes. After rinsing in distilled water, the
grids were stained for contrast with uranyl acetate. The
samples were viewed with a Tecnai Bio Twin transmission
electron microscope (FEI, Hillsboro, OR). The primary and
secondary antibodies were diluted in an incubation buffer
containing 0.1% BSA-c (AURION), 0.05% Tween in PBS.
2.5. Statistical Analysis. Comparisons between treatment
and gender groups were performed using the Student’s t-test
for unpaired samples. Two-tailed P-values (P < .05) were
used to denote statistical significance.
3. Results
The data presented below are the combination of studies
performed independently in two institutions. The 7-week
feeding study was conducted at the Mayo Clinic while
the 14-week study was performed at Indiana University—
Purdue University Indianapolis (IUPUI). The results of the
independent studies were combined after completion of
each series of experiments. Slight differences in experimental
protocols and measured parameters are a function of the
independence of study design between the institutions.
PCK rats were fed either a control diet or a diet
supplemented with pioglitazone starting after weaning. Both
male and female animals were used in the 7-week study while
the 14-week study was conducted in female rats. The data
are analyzed in a gender-specificmanner. The administration
of pioglitazone at a dose of 20mg/kg body weight was
accompanied by a significant decrease in renal cyst burden in
the male animals after only 7 weeks of pioglitazone treatment
(Table 1; Figure 1). While the decrease in renal cyst burden in
female rats did not reach statistical significance after 7 weeks
of feeding (P = .06), there was a significant decrease in the
pioglitazone-fed females after 14 weeks (Table 1; Figure 1).
Pioglitazone was also effective in decreasing the hepatic cyst
burden after 7 or 14 weeks in female rats, but had no
detectable effect on the milder liver cystic disease observed
in the male rats after 7 weeks.
Since PPARγ agonists exhibit dose-dependent, pleomor-
phic effects, we also determined the efficacy of a lower dose
of pioglitazone (4mg/kg BW) on the development of cystic
disease. Interestingly, this dose was as effective as the higher
dose in reducing the renal cyst burden in both female and
male animals (Table 2). The lower dose also decreased liver
weight as a percentage of body weight in both male and
female animals.
There was a trend for pioglitazone to reduce renal and
hepatic fibrosis. Possibly because fibrosis is mild at early
stages of the disease in this animal model, the antifibrotic
Control
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Figure 1: Effect of Pioglitazone on renal cysts in PCK rat model.
The images show transverse sections of kidneys from animals that
had been fed for 7 or 14 weeks with normal chow (control) or chow
supplemented with pioglitazone to approximate a daily treatment
of 4 or 20mg/kg BW as indicated on the figure.
effect of pioglitazone was not consistently observed and
reached statistically significance in only certain groups. In the
seven-week study, pioglitazone was effective on renal disease
in males on the low dose and on liver disease in females on
the high dose, while in the fourteen week study the agonist
was effect on renal cortical but not medullary fibrosis in the
female rats (Tables 1 and 2).
Table 3 shows the results of serum analyses conducted on
the female animals that were fed for 14 weeks. No changes
in serum parameters were found except an increase in serum
albumin. A similar profile was obtained at the 7th week time
point (data not shown).
To elucidate a mechanism for the action of pioglitazone
in cyst formation, the apical membrane expression of CFTR
in epithelial cells surrounding cysts was examined using the
monoclonal antibody 596 [19]. Figure 2 illustrates CFTR
immunoreactivity in cholangiocytes lining the liver cysts.
The CFTR-positive apical membranous staining seen in the
control tissue was diminished in the pioglitazone-treated
animals. Insufficient CFTR was present in the renal slices for
unambiguous detection of changes at the light level although
the CFTR channel is clearly present based on functional
studies [6, 9–11].
To provide a better quantitative approach, gold-labeled
immunoelectron microscopy was used to assess the density
of CFTR expression at the apical plasma membrane of the
bile duct cysts (Figure 3). Sections from 7 drug-treated and 6
control rats such as the ones shown in figure 3 were subjected
to analysis by counting the number of gold particles bound
to the surface of the apical membrane and expressing this
quantity as the number of particles per linear μm of apical
surface. A total of 36.24 linear μm of apical surface was
examined in the treated animals and 35.08 μm was examined
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Figure 2: Immunostaining for CFTR in the liver of control and pioglitazone-treated PCK rats after 14 weeks of drug treatment. Control (a)
or 20mg/kg BW pioglitazone-treated (b) liver sections were immunostained for CFTR using mAb 596. Shown in both panels is the CFTR
staining (brown) in the apical membranes of cyst-lining biliary epithelial cells. 1000x magnification.
Table 1: Effect of pioglitazone (20mg/kg body weight) on fibrocystic disease in the PCK rat model.
7-week feeding protocol
Female animals Male animals
Control
n = 8
Pioglitazone
n = 6 P-value and significance
Control
n = 5
Pioglitazone
n = 8 P-value and significance
Body weight (gr) 239± 9.48 224± 5.04 .21 NS 347± 9.50 328± 9.45 .20 NS
Kidney weight (gr) 3.74± 0.22 3.27± 0.18 .14 NS 6.64± 0.37 5.42± 0.31 .03 S
KW% BW 1.56± 0.04 1.46± 0.06 .18 NS 1.91± 0.08 1.65± 0.07 .03 S
Renal cyst vol (ml) 0.39± 0.05 0.31± 0.09 .06 NS 0.72± 0.06 0.31± 0.04 .04 S
Liver weight (gr) 13.4± 0.54 11.3± 0.43 .01 S 16.80± 0.77 15.39± 0.81 .27 NS
LW% BW 5.59± 0.12 5.03± 0.11 .01 S 4.83± 0.10 4.69± 0.18 .58 NS
Renal fibrosis 1.69± 0.53 1.25± 0.42 .12 NS 2.00± 0.32 1.81± 0.46 .45 NS
Liver fibrosis 2.44± 0.18 2.08± 0.38 .035 S 2.30± 0.27 2.19± 0.26 .48 NS
14-week feeding protocol n = 12 n = 10 P-value and significance
Body weight (gr) 315± 8.7 323± 9.7 .58 NS
Kidney weight (gr) 4.57± 0.13 3.91± 0.16 .004 S
KW% BW 1.46± 0.06 1.21± 0.04 .004 S
Renal cyst vol (ml) 0.66± 0.06 0.42± 0.09 .035 S
Liver weight (gr) 20.2± 0.76 16.0± 0.05 .0002 S
LW% BW 6.47± 0.35 4.86± 0.11 .001 S
Renal cortical fibrosis 2.69± 0.10 2.33± 0.11 .026 S
Renal medullary fibrosis 2.17± 0.10 2.09± 0.10 .569 NS
Liver fibrosis 2.46± 0.07 2.58± 0.04 .171 NS
PCK rats were fed on control or pioglitazone-supplemented diet (20mg/kg BW) from weeks 3–10 (7 weeks) or 4–18 (14 weeks). The values given are averages
± SEM. Abbreviations: KW% BW: total kidney weight as a percentage of total body weight; renal cyst vol: the estimated renal cystic volume; LW% BW:
liver weight as a percentage of total body weight. Fibrosis was scaled on a 1–4 point scale using deidentified picrosirus red stained slides of transverse kidney
sections as described in the methods section. P-values are for the comparison of control versus pioglitazone-supplemented diets by Students t-test. P less
than .05 is considered significant. NS: not significant.
from the control animals. The pioglitazone-treated tissue
showed a statistically significant decrease (P = .009) in the
number of apically localized immunolabeled CFTR antibody
particles. The biliary cysts showed an average of 1 gold-
labeled particle per 0.23 linear μm of apical surface in the
animals on the control diet and an average of 1 per 6.04 μm
in the animals treated with pioglitazone.
An overall decrease in CFTR labeling was also observed
in the immuno-gold labeled EM of renal cyst sections
taken from animals treated with pioglitazone for 14 weeks.
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Table 2: Effect of pioglitazone (4mg/kg body weight) on fibrocystic disease in the PCK rat model.
7-week feeding protocol
Female animals Male animals
Control
n = 8
Pioglitazone
n = 8 P-value and significance
Control
n = 5
Pioglitazone
n = 8 P-value and significance
Body weight (gr) 239± 9.48 236± 7.89 .82 NS 347± 9.50 342± 6.31 .68 NS
Kidney weight (gr) 3.74± 0.22 3.38± 0.19 .23 NS 6.64± 0.37 5.53± 0.20 .014 S
KW% BW 1.56± 0.04 1.43± 0.06 .103 NS 1.91± 0.08 1.61± 0.05 .007 S
Renal cyst vol 0.39± 0.05 0.30± 0.03 .016 S 0.71± 0.06 0.50± 0.03 .006 S
Liver weight (gr) 13.4± 0.54 12.4± 0.59 .24 NS 16.80± 0.77 15.16± 0.49 .085 NS
LW% BW 5.59± 0.12 5.24± 0.11 .043 S 4.83± 0.10 4.42± 0.12 .040 S
Renal fibrosis 1.69± 0.53 1.50± 0.27 .38 NS 2.00± 0.35 1.38± 0.44 .022 S
Liver fibrosis 2.44± 0.18 2.31± 0.37 .39 NS 2.30± 0.27 2.36± 0.24 .68 NS
PCK rats were fed on control or pioglitazone-supplemented diet (4mg/kg BW) from weeks 3–10 (7 weeks). The values given are averages ± SEM.
Abbreviations: KW% BW: total kidney weight as a percentage of total body weight; renal cyst vol: the estimated renal cystic volume in ml; LW% BW: liver
weight as a percentage of total body weight. Fibrosis was scaled on a 1–4 point scale using deidentified picrosirus red stained slides of transverse kidney
sections as described in the methods section. P-values are for the comparison of control versus pioglitazone-supplemented diets by Students t-test. P less
than .05 is considered significant. NS: not significant.
Table 3: Serum profiles from PCK female mice—20mg/kg BW Pioglitazone weeks 4–18.
Normal range
Control diet
n = 12 Pio diet n = 10 P-value and significance
Na+ mM 141–148 140± 0.66 139± 0.76 .442 NS
K+ mM 4.3–5.9 4.92± 1.82 4.6± 0.53 .687 NS
Cl− mM 101–108 99.7± 0.54 100.5± 0.72 .357 NS
Calcium mg/dl 9.6–11.2 10.3± 0.14 9.6± 0.36 .060 NS
BUN mg/dL 11–17 13.6± 0.53 12.4± 0.48 .118 NS
Creatinine mg/dL 0.4–0.7 0.33± 0.01 0.34± 0.03 .754 NS
Glucose mg/dL 120–186 162± 6.00 146.5± 4.59 .055 NS
Alkaline phos. U/L 65–117 315± 11.18 355± 26.67 .060 NS
Alanine aminotransferase U/L 25–45 62± 3.55 70.0± 6.71 .171 NS
Asparagine aminotransferase
U/L
72–116 136± 12.98 139.5± 20.5 .302 NS
Bilirubin mg/dL 0.2–2 0.41± 0.06 0.32± 0.04 .281 NS
Total protein gr/dL 6.4–7.5 5.5± 0.11 5.6± 0.11 .486 NS
Albumin gr/dL 3.5–5.3 1.13± 0.04 1.39± 0.03 .0001 S
Values are given as means ± SEM. Control: PCK rats on the control diet; PIO: PCK rats on a diet containing 20mg/kg body weight pioglitazone.
n: number of animals P-values greater than .05 were considered nonsignificant (NS).
However, the lower abundance of CFTR expression in the
renal cysts from both the treated and untreated animals
precluded a statistical assessment for an alteration of CFTR
immunoreactivity in the apical membrane.
4. Discussion
A variety of full and partial PPARγ agonists inhibit
vasopressin-stimulated Cl− secretion via CFTR in the
MDCK-C7 (Madin Darby Canine Kidney, clone 7) cell
culture model of the principal cells lining the distal nephron.
The dose response curves for agonist inhibition of transep-
ithelial Cl− transport paralleled the EC50 for receptor trans-
activation with a log unit leftward shift, suggesting that the
effect on Cl− secretion is very sensitive andmanifested within
serum concentrations at or below those used to treat insulin
sensitivity [6]. Based on these data, it was hypothesized that a
PPARγ-mediated decrease in the number of CFTR channels
in the epithelial cells that line PKD kidney and liver cysts
would have the effect of decreasing Cl− secretion into the cyst
lumen, thereby decreasing the osmotic driving force for fluid
accumulation.
Previous studies have examined PPARγ agonist effects
on PKD in rodent models. A functional knockout of PKD1,
the gene encoding the polycystin 1 protein, resulted in
an embryonic lethal phenotype in mice presenting with
hydrops, cardiac conotruncal defects, and renal cystogenesis
[20]. The embryos show decreased cardiac levels of c-MYC,
and abnormal metabolism of E-cadherin and PECAM-1 in
renal tubules, and hemorrhagic diathesis, the most serious
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Figure 3: Immunostaining for CFTR in the liver of control and pioglitazone-treated PCK rats after 14 weeks of drug treatment. Control (a)
or 20mg/kg BW pioglitazone-treated (b) liver sections were immunostained for CFTR with mAb 596CFTR antibody followed by a gold-
labeled secondary antibody. Shown in both panels is the CFTR staining (spherical dots) in the apical membrane sections of epithelial cells
surrounding the bile duct cysts. 49 000x magnification.
of which is hemorrhagic pericardial effusions. Maternally
administered pioglitazone at high doses (80mg/kg/day)
improved survival of the embryos by several days, amelio-
rated the cardiac defect and decreased the degree of renal
cystogenesis by an unknown mechanism [20]. In a similar
study based on the antineoplastic properties of pioglitazone,
the authors evaluated the drug’s effect in PC-Pkd1-KO mice,
a rapidly progressing model of ADPKD [21]. Feeding the
nursing mothers, and then the pups, did not alter renal
function, cell proliferation, apoptosis, or cyst formation.
However, the PPARγ agonist did increase survival and had
an antihypertensive effect. Dai and colleagues used the more
slowly progressing, Han:SPRD ratmodel to show that rosigli-
tazone (10mg/kg BW/day) was able to delay the progression
of kidney cysts and preserve renal function [22]. The authors
suggested that the mechanism of action may be due to
PPARγ agonist downregulation of an abnormally activated
β-catenin signaling pathway as well as the anti-inflammatory
and antifibrotic effects of this class of drugs. Cyst formation
in this nonorthologous model may be difficult to correlate
with human disease because the renal cysts are primarily
proximal in origin and the model does not demonstrate the
bile duct cyst formation that is common in human PKD.
Our studies, using an orthologous, slowly progressing
rat model, address the effects of PPARγ agonist treatment
early in the course of the disease but after the embryonic or
neonatal period. This preclinical model more closely mimics
the situation in potential human treatment both in the
timing of when the agonists would be administered and in
the nature of the slow disease progression. The data represent
two independent studies that were combined retrospectively.
Although there are differences in experimental protocols,
particularly with regard to the length of the feeding duration,
the strength of the findings lies in the consistency of the final
results.
In the PCK model as little as 7 weeks of pioglitazone
reduced liver cyst burden in the female animals and renal
cyst burden in the male animals. After 14 weeks on
a pioglitazone-supplemented diet, there were significant
decreases in both kidney and liver in both sexes. Cross-
sectional images of the kidney from littermates on control
or pioglitazone-supplemented diets for 14 weeks indicate
that the decrease in cyst burden is predominately due to a
decrease in cyst size. The “decrease” in cyst size is likely due
to a slower growth of the cysts in the presence of pioglitazone.
Similar to human ADPKD, the PCK rat exhibits some
gender dimorphism in the severity of the renal and hepatic
pathology [23]. Up to 18 weeks, the pathological alterations
are relatively similar in both males and females. Starting
at about 18 weeks of age, male PCK rats accelerate their
renal cystic enlargement resulting in a more severe renal
dysfunction compared to the females [13, 23]. However,
female PCK rats develop a greater liver cyst volume density
starting at 18 weeks [23]. The gender differences in efficacy
during early pioglitazone treatment may be due to subtle,
earlier gender differences in disease progression.
The serum profiles after 14 weeks of feeding indicate that
kidney function in these animals is relatively well preserved
despite the cystic burden. The blood urea nitrogen is within
the normal range and is not significantly altered by treatment
with pioglitazone. While bilirubin levels are in the normal
range, liver function as assessed by liver enzymes shows a
compromised hepatic function and this is substantiated by
the low levels of total protein and albumin in the serum.
Pioglitazone treatment did not correct the high levels of liver
enzymes but did increase the serum albumin concentration.
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The effect of pioglitazone on tissue fibrosis is more diffi-
cult to assess. In other diseases, the use of PPARγ agonists has
been correlated with decreases in inflammatory responses
and tissue fibrosis, two related processes that contribute
to organ function decline in PKD. Recent studies have
shown that PPARγ agonists can reduce fibrosis in tissues as
diverse as epidermis [24], lung [25, 26], kidney [27–30], and
liver [31–34]. These agents are effective in multiple fibrotic
diseases suggesting a commonality in the drug targets. Since
fibrosis is mild in early stages of disease progression in this
model of PKD, it is not surprising that our results regarding
the effect of PPARγ agonists are somewhat inconsistent.
Longer term studies will be necessary to clarify potential
effects on fibrotic development.
The importance of CFTR activity in renal and bile duct
cyst formation is based on functional studies. Due to low
abundance of the protein, few studies have succeeded in
detecting the protein in the apical membrane of native renal
cysts by immunohistochemical means. The demonstration
that PPARγ agonists diminish CFTR levels was initially
established in cultured cells [6]. The current studies were able
to extend the previous work to native tissue and demonstrate
that in biliary cysts, pioglitazone treatment results in a
statistically significant lower amount of the CFTR protein
in the apical membrane of the cholangiocytes lining the
cysts. These studies extend the cultured cell experiments and
provide the proof-of-principle for a mechanism whereby the
PPARγ agonists inhibit the progression of cyst growth.
The idea to use CFTR inhibitors to treat PKD is not new.
Several groups have proposed this approach [35, 36]. The
recent discovery that PPARγ agonists inhibit CFTR synthesis
provides additional possibilities using drugs that have already
undergone long-term testing in humans. Although the
PPARγ agonists can have side effects, such as fluid retention
and weight gain via adipogenesis, these are relatively mild.
However, strategies that minimize adverse events are very
important when considering treatments for a chronic disease
such as PKD. Since renal cell culture studies indicate that ago-
nist effect on CFTR occurs at concentrations approximately
an order of magnitude lower than those necessary to stabilize
insulin action [6], lower drug doses may still be effective with
minimal side effects. Of note, the lower dose of pioglitazone
was as effective in our study as the higher dose.
PPARγ agonists alter the density of CFTR expression in
the plasma membrane but do not interfere with the action of
vasopressin on water transport or cause polyuria as observed
with vasopressin V2 receptor antagonists. Moreover, PPARγ
agonists appear to be effective not only in the kidney but in
other tissues where cyst formation and growth are dependent
on CFTR-driven ion and fluid secretion. Therefore, their
possible value, either alone or in combination with other
promising therapies, in the treatment of PKD deserves
further consideration.
5. Conclusions
The studies show that a 7- or 14-week pioglitazone feeding
regimen inhibits renal and hepatic bile duct cyst growth
in the PCK rat, a rodent model orthologous to human
PKD. In bile duct cysts, the effects were accompanied by
a decrease in the apical expression of CFTR, indicating
that the mechanism of action in vivo matches previous
cell culture data that show a PPARγ-mediated decrease in
CFTR expression. In addition, in some studies, the degree
of fibrosis was diminished in pioglitazone-treated animals.
These studies provide proof-of-concept for the mechanism
of action of the PPARγ agonists and suggest that these drugs
may be effective in controlling both renal and hepatic cyst
growth and fibrosis in PKD.
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